Zalicus posted disappointing top-line results from two Phase II studies of Z160 in chronic pain indications. Z160 did not meet the primary endpoint in either study in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia (PHN). Z160 was shown to be generally safe and well-tolerated with no drug-related serious adverse events. Based on these results, Zalicus is discontinuing the Z160 program and plans to focus efforts on Z944, its novel oral T-type calcium channel modulator i...